Exelixis, Inc. (EXEL) vs Roivant Sciences Ltd. (ROIV)
- Exelixis, Inc. EXEL 62.11 −1.15%
- Roivant Sciences Ltd. ROIV 33.53 −1.50%
Exelixis, Inc. and Roivant Sciences Ltd. are both Biotechnology companies. Roivant Sciences Ltd. is the larger, with a market value of $24.6B against $15.6B — 1.6× the size. Roivant Sciences Ltd. has negative trailing earnings, so its P/E is not meaningful; Exelixis, Inc. trades at 18.8×. Exelixis, Inc. grew revenue faster over the last twelve months: 9.23% against −67.6%. Exelixis, Inc. has the higher net margin (35.3% vs −3,535.0%) and the higher return on invested capital (60.5% vs −34.5%). Across the 18 metrics below, Exelixis, Inc. leads on 16 and Roivant Sciences Ltd. on 2.
Valuation
Profitability
| Metric | EXEL | ROIV | Biotechnology median |
|---|---|---|---|
| Gross margin | 96.48% | 81.21% | 65.16% |
| Operating margin | 39.88% | (7,914.75%) | 0.00% |
| Net margin | 35.33% | (3,534.96%) | 0.00% |
| Free cash flow margin | 47.55% | (10,901.00%) | 0.00% |
| Return on equity | 44.39% | (5.47%) | (56.36%) |
| Return on assets | 33.28% | (5.15%) | (48.04%) |
| Return on invested capital | 60.45% | (34.51%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack